Norges Bank’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-2,051,899
| Closed | -$6.98M | – | 2147 |
|
|
2018
Q3 | $6.98M | Hold |
2,051,899
| – | – | ﹤0.01% | 1912 |
|
|
2018
Q2 | $7.71M | Hold |
2,051,899
| – | – | ﹤0.01% | 1875 |
|
|
2018
Q1 | $8.39M | Hold |
2,051,899
| – | – | ﹤0.01% | 1794 |
|
|
2017
Q4 | $9.54M | Hold |
2,051,899
| – | – | ﹤0.01% | 1755 |
|
|
2017
Q3 | $14.6M | Buy |
2,051,899
+46,103
| +2% | +$332K | 0.01% | 1605 |
|
|
2017
Q2 | $14.5M | Buy |
2,005,796
+303,861
| +18% | +$1.9M | 0.01% | 1597 |
|
|
2017
Q1 | $10.5M | Hold |
1,701,935
| – | – | ﹤0.01% | 1719 |
|
|
2016
Q4 | $9.97M | Hold |
1,701,935
| – | – | ﹤0.01% | 1687 |
|
|
2016
Q3 | $8.63M | Hold |
1,701,935
| – | – | ﹤0.01% | 1719 |
|
|
2016
Q2 | $11.3M | Hold |
1,701,935
| – | – | 0.01% | 1547 |
|
|
2016
Q1 | $7.95M | Sell |
1,701,935
-110,000
| -6% | -$439K | ﹤0.01% | 1675 |
|
|
2015
Q4 | $9.15M | Buy |
1,811,935
+870,000
| +92% | +$4.13M | ﹤0.01% | 1645 |
|
|
2015
Q3 | $3.32M | Hold |
941,935
| – | – | ﹤0.01% | 1956 |
|
|
2015
Q2 | $9.4M | Buy |
941,935
+336,415
| +56% | +$3.61M | ﹤0.01% | 1656 |
|
|
2015
Q1 | $7.71M | Buy |
+605,520
| New | +$7.78M | ﹤0.01% | 1762 |
|
Norges Bank's KERX Position: Q4 2018 in Review
Norges Bank sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 2,051,899 shares — an estimated $6.98M sold.
Norges Bank first reported a position in KERX in Q1 2015 and held it in 15 quarters. The position peaked at $14.6M in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Norges Bank reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Norges Bank sold 2,051,899 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $6.98M.
- Norges Bank first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 15 quarters.
- Norges Bank's Keryx Biopharmaceuticals Inc position peaked at $14.6M in Q3 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Norges Bank's 13F filing for Q4 2018, filed 8 Feb 2019.